Adjuvance Technologies, Inc.
Investors
Adjuvance Technologies is a privately owned company and is currently seeking capital investment -- primarily to help close our funding gap and finance the initial large-scale production of our lead molecules for supply to vaccine manufacturers on an investigational basis.
Adjuvance Technologies represents a unique opportunity to invest in an early stage biopharmaceutical company that has a compelling value proposition, a top-notch team, an exceptional set of competitive advantages, a powerful business model and a clinically advanced platform.
Parties interested in investing in Adjuvance Technologies or obtaining Adjuvance’s Executive summary should contact us for information about their possible collaboration with Adjuvance.